Drugs / EDP2939
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05682222 | Jun → Oct 2022 | — | Evelo Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EDP2939 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05682222 ↗ |
| Modality | Other / unclassified | “EDP2939 is a pharmaceutical preparation of extracellular vesicles.” NCT05682222 ↗ |
| Route | Oral | “EDP2939 lower dose or placebo in capsule B, dosed for 60 days.” NCT05682222 ↗ |